|
10 Aug 2022 |
Aridis' Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective in Non-Human Primates
|
|
10 Aug 2022 |
Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers
|
|
10 Aug 2022 |
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results
|
|
10 Aug 2022 |
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint
|
|
10 Aug 2022 |
Upstream Bio Announces Dosing of First Patient in a Phase 1b Clinical Trial of UPB-101 in Asthma
|
|
10 Aug 2022 |
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
|
|
10 Aug 2022 |
Datopotamab deruxtecan-based combinations show promising clinical activity in patients with advanced non-small cell lung cancer
|
|
09 Aug 2022 |
TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
|
|
09 Aug 2022 |
Amgen presents new tarlatamab clinical data at WCLC 2022
|
|
08 Aug 2022 |
HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
|
|
08 Aug 2022 |
Innovent Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema
|
|
06 Aug 2022 |
Enhertu approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
|
|
05 Aug 2022 |
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
|
|
04 Aug 2022 |
Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
|
|
04 Aug 2022 |
Eisai presents new findings on lecanemab's investigational subcutaneous formulation and modeling simulation of ApoE4 genotype on ARIA-E incidence at the Alzheimer's Association International Conference (AAIC) 2022
|
|
04 Aug 2022 |
ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial
|
|
03 Aug 2022 |
ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medical Officer
|
|
03 Aug 2022 |
Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
|
|
03 Aug 2022 |
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
|
|
03 Aug 2022 |
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
|
|
03 Aug 2022 |
Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
|
|
03 Aug 2022 |
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity
|
|
03 Aug 2022 |
Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma
|
|
02 Aug 2022 |
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8009, an Antibody Drug Conjugate Targeting B7-H3 (CD276) for the Treatment of Advanced Solid Tumors
|
|
02 Aug 2022 |
Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results
|
